Selective Inhibition of the Immunoproteasome β5i Prevents PTEN Degradation and Attenuates Cardiac Hypertrophy
Open Access
- 12 June 2020
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 11, 885
- https://doi.org/10.3389/fphar.2020.00885
Abstract
Cardiac hypertrophy without appropriate treatment eventually progresses to heart failure. Our recent data demonstrated that the immunoproteasome subunit beta 5i promotes cardiac hypertrophy. However, whether beta 5i is a promising therapeutic target for treating hypertrophic remodeling remains unknown. Here, we investigated the effects of PR-957, a beta 5i-specific inhibitor, on angiotensin II (Ang II)-induced hypertrophic remodeling in the murine heart. The infusion of Ang II increased immunoproteasome chymotrypsin-like activity and beta 5i catalytic subunit expression in the heart, whereas PR-957 treatment fully blocked the enhanced immunoproteasome activity caused by Ang II. Moreover, the administration of PR-957 significantly suppressed Ang II-induced cardiac hypertrophy, fibrosis, and inflammation. Mechanistically, PR-957 treatment inhibited phosphatase and tensin homolog on chromosome ten (PTEN) degradation, thereby inhibiting multiple signals including AKT/mTOR, ERK1/2, transforming growth factor-beta, and IKB/NF-kB. Furthermore, PTEN blocking by its specific inhibitor VO-OHpic markedly attenuated the inhibitory effect of PR-957 on Ang II-induced cardiac hypertrophy in mice. We conclude that PR-957 blocks PTEN degradation and activates its downstream mediators, thereby attenuating Ang II-induced cardiac hypertrophy. These findings highlight that PR-957 may be a potential therapeutic agent for Ang II-induced hypertrophic remodeling.Funding Information
- National Natural Science Foundation of China (81570207, 81330003, 81630009, 81600315)
This publication has 27 references indexed in Scilit:
- Genetic ablation and pharmacological inhibition of immunosubunit β5i attenuates cardiac remodeling in deoxycorticosterone-acetate (DOCA)-salt hypertensive miceJournal of Molecular and Cellular Cardiology, 2019
- Fibrosis Rescue Improves Cardiac Function in Dystrophin-Deficient Mice and Duchenne Patient–Specific Cardiomyocytes by Immunoproteasome ModulationThe American Journal of Pathology, 2018
- Resveratrol as a new inhibitor of immunoproteasome prevents PTEN degradation and attenuates cardiac hypertrophy after pressure overloadRedox Biology, 2018
- The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditisEMBO Molecular Medicine, 2018
- Role of ubiquitin-proteasome system (UPS) in left ventricular hypertrophy (LVH).2014
- Immune and non-immune functions of the immunoproteasomeFrontiers in Bioscience-Landmark, 2012
- A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myelomaBlood, 2010
- Ischemic preconditioning‐induced cardioprotection is lost in mice with immunoproteasome subunit low molecular mass polypeptide‐2 deficiencyThe FASEB Journal, 2008
- Activation of the Cardiac Proteasome During Pressure Overload Promotes Ventricular HypertrophyCirculation, 2006
- Akt induces enhanced myocardial contractility and cell size in vivo in transgenic miceProceedings of the National Academy of Sciences of the United States of America, 2002